UK's Niox revenue up 17%, ahead of market expectations

Niox

20/01/2026 07:11

Overview

UK medical device firm's revenue grew 17% to £48.7 mln, exceeding market expectations

Adjusted EBITDA rose 21% to £16.7 mln, beating consensus expectations

Company launched new NIOX PRO® device with first sale in December 2025

Outlook

Company expects future research sales to align with historical levels

Niox aims to drive further adoption of FeNO testing worldwide

Company sees strong commercial momentum entering 2026

Result Drivers

RESEARCH SALES - Research revenue grew 77% due to increased clinical trial activity involving FeNO testing for asthma and COPD

NIOX PRO® LAUNCH - Successful introduction of next-generation NIOX PRO® device with first sale in December 2025

DIRECT SALES MODEL - Transition to direct US sales model expected to support stronger growth in Clinical business

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Revenue
GBP 48.70 mln
FY Gross Margin
69.00%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Niox Group PLC is GBP83.00, about 20.6% above its January 19 closing price of GBP68.80

The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 23 three months ago

Press Release: ID:nRST5034Pa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)